Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07117487 · ClinicalTrials.gov registry record · Phase 3
A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age
A Phase 3 study of Respiratory Syncytial Virus, sponsored by ModernaTX.
- Active
- Registry status
- Phase 3
- Development phase
- 507
- Enrollment target
- 11
- Study locations
NCT07117487: Active Phase 3 study of Respiratory Syncytial Virus, sponsored by ModernaTX.
NCT07117487 is a Phase 3 study of Respiratory Syncytial Virus that is active but no longer recruiting, run by ModernaTX. The registered enrollment target is 507 participants, above the 325-participant average among 7 other Respiratory Syncytial Virus trials with a reported enrollment target (56% higher). The trial reports 11 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07117487, a Phase 3 study of Respiratory Syncytial Virus, is active but no longer recruiting, sponsored by ModernaTX.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 507 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this study is to evaluate safety, tolerability and immunogenicity of mRNA-1345 in participants who have been previously vaccinated with either Arexvy or Abrysvo at least 12 months prior to enrollment, are medically stable and aged ≥60 years.
Conditions Studied
Interventions
- BIOLOGICAL mRNA-1345
Study Locations (11)
Colorado
- Velocity Clinical Research, Denver - Denver
Florida
- Indago Research & Health Center, Inc. - Hialeah
Georgia
- Velocity Clinical Research, Savannah - Savannah
Indiana
- Velocity Clinical Research, Valparaiso - Valparaiso
Louisiana
- Velocity Clinical Research, Covington - Covington
Maryland
- Velocity Clinical Research, Rockville - Rockville
Nebraska
- Velocity Clinical Research, Lincoln - Lincoln
Oregon
- Velocity Clinical Research, Medford - Medford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 507 participants |
| Start Date | 2025-08-05 |
| Est. Completion | 2026-04-15 |
| Phase | Phase 3 |
What the registry record for NCT07117487 still lists
NCT07117487 is an interventional study that assigns participants to a tested intervention. The registered 507 participants enrollment target is mid-sized for trials with a published cap, above the 325-participant average among 7 other Respiratory Syncytial Virus trials with a reported enrollment target (56% higher).
The record links to 1 condition, with Respiratory Syncytial Virus appearing as the primary indexed condition, and to 1 intervention - of which mRNA-1345 is the first listed.
NCT07117487 lists 11 locations in 11 states (Colorado, Florida, Georgia).
Frequently Asked Questions
What is clinical trial NCT07117487 about?
NCT07117487 is a clinical study titled "A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age". The purpose of this study is to evaluate safety, tolerability and immunogenicity of mRNA-1345 in participants who have been previously vaccinated with either Arexvy or Abrysvo at least 12 months prior to enrollment, are medically stable and aged ≥60 years.
What is the current status of trial NCT07117487?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 507 participants. The study started on 2025-08-05. Estimated completion is 2026-04-15.
What conditions does trial NCT07117487 study?
This clinical trial studies the following conditions: Respiratory Syncytial Virus.
What interventions are being tested in trial NCT07117487?
The interventions under investigation include: mRNA-1345 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07117487?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07117487 being conducted?
This trial has 11 study locations across Colorado, Florida, Georgia, Indiana, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Respiratory Syncytial Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults
ACTIVE NOT RECRUITING · Phase 3
-
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months
ACTIVE NOT RECRUITING · Phase 1
-
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers
ACTIVE NOT RECRUITING · Phase 2
-
Dose, Safety, Tolerability and Immunogenicity of a Stabilized Prefusion RSV F Subunit Protein Vaccine, VRC-RSVRGP084-00-VP (DS-Cav1), Alone or With Alum Adjuvant, in Healthy Adults
COMPLETED · Phase 1
-
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus
COMPLETED · Phase 2
-
A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06164717 · 507 participants · NA
Behavioral and Neural Characteristics of Adaptive Speech Motor Control
- NCT02115295 · 508 participants · Phase 2
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
- NCT04692675 · 508 participants · NA
Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer
- NCT07391657 · 508 participants · Phase 3
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI